CFGS
ANIK icon

Concourse Financial Group Securities’s Anika Therapeutics ANIK Stock Holding History

Concourse Financial Group Securities’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29
Closed -$1.19K – 2396
2021
Q2 		$1K Hold
29
– – ﹤0.01% 2263
2021
Q1 		$1K Sell
29
-55
-65% -$2.09K ﹤0.01% 2203
2020
Q4 		$4K Sell
84
-36
-30% -$1.37K ﹤0.01% 1960
2020
Q3 		$4K Buy
+120
New +$4.33K ﹤0.01% 1838

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Concourse Financial Group Securities's ANIK Position: Q3 2021 in Review

Concourse Financial Group Securities sold out of Anika Therapeutics (ANIK) in Q3 2021, closing a stake of 29 shares — an estimated $1.19K sold.

Concourse Financial Group Securities first reported a position in ANIK in Q3 2020 and held it in 4 quarters. The position peaked at $4K in Q4 2020. 131 funds tracked by Wall St. Rank hold ANIK as of Q3 2021.

  • Concourse Financial Group Securities reported no remaining Anika Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Concourse Financial Group Securities sold 29 Anika Therapeutics shares in Q3 2021, an estimated $1.19K.
  • Concourse Financial Group Securities first reported a position in Anika Therapeutics in Q3 2020 and held it in 4 quarters.
  • Concourse Financial Group Securities's Anika Therapeutics position peaked at $4K in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2021.

Based on Concourse Financial Group Securities's 13F filing for Q3 2021, filed 9 Nov 2021.